Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.
Also called NCT01413048
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 260 participants
- Registry
-
NCT01413048
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT01413048. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2012-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Evaluate the Antihypertensive Effect of AGSCT101 in Patient With Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Carvedilol 25mg
- Intervention (Drug)
- AGSCT101 12.5mg
- Lead sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Record details
- Record id
cardio:ct-nct01413048- Content hash
91d468272e992bbff6dc2efea274dea98444bd29535e0554b3bb8b015c81733e